My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Rosiglitazone HCl
    Rosiglitazone HCl

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0838
    CAS #: 302543-62-0Purity ≥98%

    Description: Rosiglitazone HCl (HSDB-7555; BRL-49653; TDZ-01; BRL49653), the hydrochloride salt of Rosiglitazone, is a potent antidiabetic/antihyperglycemic drug of the thiazolidinedione class with anti-inflammatory activities. It acts as a potent insulin sensitizer with IC50s of 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively. It is also a selective PPARγ agonist which activates PPARγ1/γ2/γ with EC50s of 30 nM, 100 nM and 60 nM, respectively. Rosiglitazone binds to the PPAR receptors in fat cells and making the cells more responsive to insulin. 

    References: J Biol Chem. 2002 Jul 12;277(28):25226-32; Endocrinology. 2004 Jan;145(1):401-6. 

    Related CAS #: 155141-29-0 (Rosiglitazone maleate)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)393.89
    CAS No.302543-62-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 79 mg/mL (200.6 mM)
    Water: <1 mg/mL
    Ethanol: 79 mg/mL (200.6 mM)
    Chemical Name

    5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride

    SynonymsRosiglitazone HCl; Rosiglitazone Hydrochloride; HSDB-7555; BRL-49653 HCl; BRL49653; TDZ-01; BRL 49653; HSDB 7555; HSDB7555; TDZ 01; TDZ01; Rosiglitazone. trade name Avandia.

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Rosiglitazone is an insulin-sensitising agent of the thiazolidinedione class of oral antihyperglycaemic drugs. Rosiglitazone exhibits insulin-sensitising activity 60- to 200-fold higher than that of troglitazone, englitazone, or piogliazone in rodent models of insulin ressitance. Rosiglitazone reduces hyperglycaemia by improving insulin sensitivity in adipose tissue, the liver and skeletal muscle tissue. Such insulin sensitisation may be partly attributable to the effects of Rosiglitazone on the expression of molecules involved in the insulin signalling cascade. In adipose tissue, Rosiglitazone-mediated PPARγ stimulation promotes adipocyte differentiation. Rosiglitazone may also promote the uptake of free fatty acids in adipose tissue, thus reducing systemic free fatty acid levels. The insulin sensitivity of the liver and peripheral tissues may be modulated indirectly by Rosiglitazone-mediated changes in levels of fatty acid or adipocyte-derived factors, such as adiponectin and TNFα. Rosiglitazone may also be involved in modulating the expression of adiponectin receptors in some tissues, which may be relevant to some aspects of insulin sensitization.

    Kinase Assay: cDNA encoding amino acids 174-475 of PPARγ1 is amplified via polymerase chain reaction and inserted into bacterial expression vector pGEX-2T. GST-PPARγ LBD is expressed in BL21(DE3)plysS cells and extracts. For saturation binding analysis, bacterial extracts (100 μg of protein) are incubated at 4°C for 3 h in buffer containing 10 mM Tris (pH 8.0), 50 mM KCl, 10 mM dithiothreitol with [3H]-BRL49653 (specific activity, 40 Ci/mmol) in the presence or absence of unlabeled Rosiglitazone. Bound is separated from free radioactivity by elution through 1-mL Sephadex G-25 desalting columns. Bound radioactivity eluted in the column void volume and is quantitated by liquid scintillation counting.

    Cell Assay: C3H10T1/2 cells are grown in a 24-well plate in DME medium supplemented with 10% fetal calf serum. Medium and compound (Rosiglitazone) are exchanged every 3 days. Cells are stained at day 7 with Oil Red O and photographed

    In VivoRosiglitazone (5 mg/kg, p.o.) decreases the serum glucose in diabetic rats. Rosiglitazone also decreases IL-6, TNF-α, and VCAM-1 levels in diabetic group. Rosiglitazone in combination with losartan increases glucose compared to diabetic and Los-treated groups. Rosiglitazone significantly ameliorates endothelial dysfunction indicated by a significantly lower contractile response to PE and Ang II and enhancement of ACh-provoked relaxation in aortas isolated from diabetic rats.
    Animal modelRats
    Formulation & DosageRats are intravenously injected with 38 mg/kg streptozotocin and after 48 h, diabetes is identified by urinary glucosuria and then random blood sugar is measured and this day is regarded as day 0. Animals with a serum glucose level of 220-300 mg/dL are selected to be used in this study. Rats are randomly separated into five groups for daily drug administration for 8 weeks: group 1: control nondiabetic rats given a vehicle only (0.5 mL/kg of 0.5% carboxy methyl celleluse orally), group 2: control diabetic rats given a vehicle, group 3: diabetic rats receiving Rosiglitazone (5 mg/kg orally), group 4: diabetic rats receiving losartan (2 mg/kg, orally), and group 5: diabetic rats receiving both Rosiglitazone and losartan

    [1]. Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.

    [2]. Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.

    [3]. Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70.

    [4]. Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30.

    [5]. Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220.

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Rosiglitazone HCl

    The PPARγ agonist rosiglitazone partially reverses the effect of GCN2 deficiency on liver and serum triglycerides and lipid droplet protein expression. PLoS One. 2013; 8(10): e75917.

    Rosiglitazone HCl

    Administration of α-GalCer induces activation of CD4+ T cells in myometrial tissues that is reduced by rosiglitazone.

    Rosiglitazone HCl

    Administration of α-GalCer induces an expansion of activated CD1d-restricted iNKT cells in decidual tissues, which is blunted by rosiglitazone. J Immunol. 2016 Feb 1; 196(3): 1044–1059.


    Rosiglitazone HCl

    Administration of α-GalCer induces activation of innate immune cells at the maternal-fetal interface that is blunted by rosiglitazone.

    Rosiglitazone HCl

    Rosiglitazone treatment reduces the rate of α-GalCer-induced late PTB by inducing PPARγ activation at the maternal-fetal interface. J Immunol. 2016 Feb 1; 196(3): 1044–1059.

    Rosiglitazone HCl

    Body and organ weights of animals fed for 7 wk with either nonsupplemented (gray bar) or rosiglitazone-supplemented (black bar) diet. Endocrinology. 2004 Jan;145(1):401-6.
    Rosiglitazone HCl
    DXA of total-body BMD.

    Rosiglitazone HCl

    Micro-CT representative renderings of proximal tibia from control and rosiglitazone-treated animals were generated as described in Materials and Methods. Endocrinology. 2004 Jan;145(1):401-6.

    Rosiglitazone HCl

    Representative photomicrographs of cancellous tibia.

    Rosiglitazone HCl

    Liver histological cross-sections representative for each group. Endocrinology. 2004 Jan;145(1):401-6.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?